If your oHCM symptoms are returning or your energy is flagging, your treatment plan may need an update. Here's how to talk to ...

Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

By Sneha S K May 5 (Reuters) - Cytokinetics said on Tuesday its experimental heart disease drug significantly improved symptoms of a genetic heart condition in a late-stage trial, sending its shares ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (MyoKardia) is a novel, oral, allosteric modulator of cardiac myosin. This therapy was specifically ...

Robert Blum and Fady Malik, M.D., Ph.D, have been with Cytokinetics since its inception nearly three decades ago. | ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

Topline results announced today show gains in KCCQ and peak oxygen consumption—the full dataset is coming soon.

Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

The ACACIA-HCM trial met both primary endpoints, potentially opening treatment to a new population of heart disease patients ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...